Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Nyse  >  Merck & Co., Inc.    MRK


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Merck & Co., Inc : In an accumulation phase

04/14/2020 | 01:03pm EST
long trade
Stop-loss triggered
Entry price : 82.375$ | Target : 95.7$ | Stop-loss : 75.7$ | Potential : 16.18%
An exit from the recently observed accumulation phase to the upside could allow for the assumption that a clear upward trend is re-established with an increase in volatility.
Investors have an opportunity to buy the stock and target the $ 95.7.
Merck & Co., Inc : Merck & Co., Inc : In an accumulation phase
  • The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
  • The company has solid fundamentals for a short-term investment strategy.

  • The group's activity appears highly profitable thanks to its outperforming net margins.
  • Over the last twelve months, the sales forecast has been frequently revised upwards.
  • For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
  • Analysts covering this company mostly recommend stock overweighting or purchase.

  • The group usually releases earnings worse than estimated.
  • Based on current prices, the company has particularly high valuation levels.
  • Analysts covering the stock have recently lowered their earnings forecast.

© MarketScreener.com 2020
Stocks mentioned in the article
ChangeLast1st jan.
AT HOME GROUP INC. -2.28% 25.31 Delayed Quote.67.53%
MERCK & CO., INC. -3.96% 77.07 Delayed Quote.-1.89%

Disclaimer: The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.

Financials (USD)
Sales 2020 48 203 M - -
Net income 2020 12 158 M - -
Net Debt 2020 15 159 M - -
P/E ratio 2020 16,9x
Yield 2020 3,05%
Capitalization 203 B 203 B -
EV / Sales 2020 4,53x
EV / Sales 2021 4,17x
Nbr of Employees 71 000
Free-Float 70,7%
Upcoming event on MERCK & CO., INC.
Income Statement Evolution
Mean consensus BUY
Number of Analysts 23
Average target price 97,05 $
Last Close Price 80,25 $
Spread / Highest target 33,3%
Spread / Average Target 20,9%
Spread / Lowest Target 5,92%
EPS Revisions
Managers and Directors
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis CFO & Executive Vice President-Global Services
Sandy Tremps Vice President-R&D IT CIO
Thomas Henry Glocer Independent Director
Leslie A. Brun Lead Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
MERCK & CO., INC.-1.89%203 035
JOHNSON & JOHNSON8.32%448 796
ROCHE HOLDING AG4.51%312 213
NOVARTIS AG0.81%214 457
PFIZER INC.1.36%207 384